Gilead published clinical data on GS-9688, a new functional drug for hepatitis B

recently, Gilead, the US pharmaceutical giant, released new clinical data on
, a functional cure for hepatitis B.About GS-9688GS-9688 is an oral, selective tooll-like subject 8 (TLR8) small molecular agonist.In a multi-center, randomized, double-blind Phase II study of 48 patients with chronic HBV infections who had achieved virological suppression, GS-9688 (once a week oral) combined oral antiviral drugs (OAVs) were well toned during extended administration and showed pharmacological activity of dose dependence.The clinical activity of GS-9688 was also assessed: 5% of patients treated with GS-9688 had a decrease in HBSAg or HBeAg levels ≥1 log10IU/mL at the 24th week of treatment.data support ongoing GS-9688 studies and new combinations aimed at achieving functional cures for HBV.The safety and ability of GS-9688 has not been determined, and the drug is a research compound that has not been approved by the FDA or any other regulatory agency. (Drug Information Network)
)